CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 403 enrolled
Drug / intervention
Insulin Lispro Mix25 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01773473
NCT01773473Phase 4Completed
CompareCT.gov

Comparison Between Low Mixed Insulin and Mid Mixed Insulin AS Starter Insulin For Patients With TYpe 2 Diabetes Mellitus (CLASSIFY Study)

Eli Lilly and Company·interventional·Posted Jan 23, 2013·Updated May 21, 2015

In Brief

A Phase 4 clinical trial evaluating Insulin Lispro Mix25 and Insulin Lispro Mix50 for Type 2 Diabetes Mellitus. Completed, enrolled 403 participants across 27 sites in 4 countries.

Detailed Summary

The purpose of this study is to determine the efficacy and safety of insulin Lispro Mix25 (LM25) compared to insulin Lispro Mix50 (LM50) as an insulin starter in participants with Type 2 diabetes mellitus (T2DM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesChina, Japan, South Korea, Turkey (Türkiye)
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 23, 2013
Enrollment StartJan 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.4 years ago

Interventions

Insulin Lispro Mix25drug

Administered SC

Insulin Lispro Mix50drug

Administered SC